

## Certificate of Analysis

[www.tocris.com](http://www.tocris.com)

**Product Name:** [Ala<sup>92</sup>]-p16 (84-103)

**Catalog No.:** 1902

**Batch No.:** 1

**CAS Number:** 189064-08-2

### 1. PHYSICAL AND CHEMICAL PROPERTIES

**Batch Molecular Formula:** C<sub>93</sub>H<sub>155</sub>N<sub>31</sub>O<sub>26</sub>  
**Batch Molecular Weight:** 2123.44  
**Physical Appearance:** White lyophilised solid  
**Net Peptide Content:** 72%  
**Solubility:** Soluble to 2 mg/ml in water  
**Storage:** Desiccate at -20°C  
**Peptide Sequence:** Asp-Ala-Ala-Arg-Glu-Gly-Phe-Leu-Ala-Thr-Leu-Val-Val-Leu-His-Arg-Ala-Gly-Ala-Arg

### 2. ANALYTICAL DATA

**HPLC:** Shows >95% purity

### 3. AMINO ACID ANALYSIS DATA

Amino Acid		Theoretical	Actual	Amino Acid		Theoretical	Actual
Ala	5.00	4.82	Lys				
Arg	3.00	3.02	Met				
Asx	1.00	0.98	Phe	1.00	1.01		
Cys			Pro				
Glx	1.00	0.98	Ser				
Gly	2.00	2.00	Thr	1.00	0.92		
His	1.00	1.01	Trp				
Ile			Tyr				
Leu	3.00	2.89	Val	2.00	1.55		

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

**Product Name:** [Ala<sup>92</sup>]-p16 (84-103)

**Catalog No.:** 1902

**Batch No.:** 1

CAS Number: 189064-08-2

**Description:**

Peptide derived from the tumor suppressor protein p16; inhibits cyclin-dependent kinase-4 (cdk4)/cyclin D1 (IC<sub>50</sub> ~ 1.5 µM) and binds to cdk6.

**Physical and Chemical Properties:**

Batch Molecular Formula: C<sub>93</sub>H<sub>155</sub>N<sub>31</sub>O<sub>26</sub>

Batch Molecular Weight: 2123.44

Physical Appearance: White lyophilised solid

**Peptide Sequence:**

Asp-Ala-Ala-Arg-Glu-Gly-Phe-Leu-Ala-Thr-  
Leu-Val-Val-Leu-His-Arg-Ala-Gly-Ala-Arg

**Storage:** Desiccate at -20°C

**Solubility & Usage Info:**

Soluble to 2 mg/ml in water

This product is supplied as a lyophilized solid and may be very hard to visualize. Solutions should be made by adding solvent directly to the vial. The vial should then be vortexed vigorously to ensure the product has completely dissolved.

**Net Peptide Content:** 72% (Remaining weight made up of counterions and residual water).

**Stability and Solubility Advice:**

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Peptides in solution are much less stable than in lyophilized form. This is especially true for peptides whose sequences contain amino acids such as Cys, Met, Trp, Asn, Gln, and N-terminal Glu.

Therefore we recommend storing peptides in solution for as short a time as possible. Avoid repeated freeze thaw cycles by dividing the peptide solution into aliquots and storing the aliquots at -20°C. Any portion of an aliquot unused after thawing should be discarded.

Peptides stored in solution can occasionally be susceptible to bacterial degradation. We recommend using sterile solutions or passing the peptide solution through a 0.2 µm filter to remove potential bacterial contamination whenever possible.

**References:**

**Fahraeus et al** (1998) Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule. *Oncogene* **16** 587. PMID: 9482104.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

**bio-techne.com**

info@bio-techne.com

techsupport@bio-techne.com

**North America**

Tel: (800) 343 7475

**China**

info.cn@bio-techne.com

Tel: +86 (21) 52380373

**Europe Middle East Africa**

Tel: +44 (0)1235 529449

**Rest of World**

www.tocris.com/distributors

Tel: +1 612 379 2956